|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Present and future of metastatic colorectal cancer treatment: A review of new candidate targets显示文摘In the last two decades, great efforts have been made in the treatment of metastatic colorectal cancer(m CRC) due to the approval of new target agents for cytotoxic drugs. Unfortunately, a large percentage of patients present with metastasis at the time of diagnosis or relapse after a few months. The complex molecular heterogeneity of this disease is not completely understood; to date, there is a lack of predictive biomarkers that can be used to select subsets of patients who may respond to target drugs. Only the RAS-mutation status is used to predict resistance to anti-epidermal growth factor receptor agents in patients with m CRC. In this review, we describe approved targeted therapies for the management of metastatic m CRC and discuss new candidate targets on the horizon. | Giulia Martini Teresa Troiani Claudia Cardone Pietropaolo Vitiello Vincenzo Sforza Davide Ciardiello Stefania Napolitano Carminia Maria Della Corte Floriana Morgillo Antonio Raucci Antonio Cuomo Francesco Selvaggi Fortunato Ciardiello Erika Martinelli | 2017 | World Journal of Gastroenterology2017，23，26： | 7 |
| 2 | Mechanisms of resistance to anti-epidermal growth factor receptor inhibitors in metastatic colorectal cancer显示文摘The prognosis of patients with metastatic colorectal cancer(m CRC) remain poor despite the impressive improvement of treatments observed over the last 20 years that led to an increase in median overall survival from 6 mo, with the only best supportive care, to approximately 30 mo with the introduction of active chemotherapy drugs and targeted agents. The monoclonal antibodies(mo Abs) cetuximab and panitumumab, directed against the epidermal growth factor receptor(EGFR), undoubtedly represent a major step forward in the treatment of m CRC, given the relevant efficacy in terms of progression-free survival, overall survival, response rate, and quality of life observed in several phase Ⅲ clinical trials among different lines of treatment. However, the anti-EGFR mo Abs were shown only to be effective in a subset of patients. For instance, KRAS and NRAS mutations have been identified as biomarkers of resistance to these drugs, improving the selection of patients who might derive a benefit from these treatments. Nevertheless, several other alterations might affect the response to these drugs, and unfortunately, even the responders eventually become resistant by developing secondary(or acquired) resistance in approximately 13-18 mo. Several studies highlighted that the landscape of responsible alterations of both primary and acquired resistance to anti-EGFR drugs biochemically converge into MEK-ERK and PIK3CA-AKT pathways. In this review, we describe the currently known mechanisms of primary and acquired resistance to anti-EGFR mo Abs together with the various strategies evaluated to prevent, overcame or revert them. | Vincenzo Sforza Erika Martinelli Fortunato Ciardiello Valentina Gambardella Stefania Napolitano Giulia Martini Carminia della Corte Claudia Cardone Marianna L Ferrara Alfonso Reginelli Giuseppina Liguori Giulio Belli Teresa Troiani | 2016 | World Journal of Gastroenterology2016，22，28： | 6 |
| 3 | Optimizing treatment of metastatic colorectal cancer patients with anti-EGFR antibodies: overcoming the mechanisms of cancer cell resistance显示文摘 | Teresa Troiani Silvia Zappavigna Erika Martinelli Santolo R. Addeo Paola Stiuso Fortunato Ciardiello Michele Caraglia | 2013 | Expert Opinion on Biological Therapy2013，，2： | 2 |
| 4 | Antitumor activity of pimasertib, a selective MEK 1/2 inhibitor, in combination with PI3K/mTOR inhibitors or with multi‐targeted kinase inhibitors in pimasertib‐resistant human lung and colorectal cancer cells显示文摘 | Erika Martinelli Teresa Troiani Elena D’Aiuto Floriana Morgillo Donata Vitagliano Anna Capasso Sarah Costantino Loreta Pia Ciuffreda Francesco Merolla Loredana Vecchione Veerle Vriendt Sabine Tejpar Anna Nappi Vincenzo Sforza Giulia Martini Liberato Berri | 2013 | Int J Cancer2013，，9： | 2 |
| 5 | A phase II study of neoadjuvant bevacizumab plus capecitabine and concomitant radiotherapy in patients with locally advanced rectal cancer显示文摘 | Giampietro Gasparini Francesco Torino Takayuki Ueno Stefano Cascinu Teresa Troiani Alberto Ballestrero Rossana Berardi Junichi Shishido Akihiko Yoshizawa Yukiko Mori Satoshi Nagayama Paola Morosini Masakazu Toi | 2012 | Angiogenesis2012，，1： | 2 |
| 6 | Direct observation of the mechanical properties of single wall carbon nanotubes and their heterojunctions at the atomic level显示文摘 | Troiani H E Miki-Yoshida M Camacho-Bragado G A | 2003 | Nano Lett2003，3，6： | 1 |
| 7 | Hearing loss in older adults affects neural systems supporting speech comprehension显示文摘 | Peelle JE Troiani V Grossman M | 2011 | J Neurosci2011，31，12： | 1 |
| 8 | Family functioning in anorexia nervosa differs by subtype 显示文摘 | Casper R Troiani M | 2001 | Int J Eat Disord2001，30，3： | 1 |
| 9 | Sequence-dependent,synergistic antiproliferative and proapoptic effects of the combination of cytotoxic drugs and enzastaurum,a protein kinase Cβ inhibitor in non-small cell lung cancer cells显示文摘 | Morgillo F Martinelli E Troiani T | 2008 | Mol Cancer Ther2008，17，6： | 1 |
| 10 | alphaTocopherol protective effects on gentamicin ototoxicity: an experimental study显示文摘 | Fetoni AR Sergi B Ferraresi A Paludetti G Troiani D | 2004 | Int J Audiol2004，43，3： | 1 |
| 11 | Combining trgeted therapies and drugs with multiple targets in the treatment of NSCLC 显示文摘 | Maione P Gridelli C Troiani T | 2006 | Oncologist2006，11，3： | 1 |
| 12 | Effect of velocity inflow conditions on the stability of a CH4/air jet-flame显示文摘 | Troiani G | | 0，，02： | 1 |
| 13 | Antioxidant effects of an aqueous extract of Ilex paraguariensis显示文摘 | Troiani G Dávila V | 2000 | Biochemical and Biophysical Research Communications2000，，269： | 1 |
| 14 | The use of xenografi models for the selection of cancer treatments with the EGFR as an example显示文摘 | Troiani T Schettino C Martinelli E | 2008 | Crit Rev Oncol Hematol2008，65，3： | 1 |
| 15 | Panitumumab , the evidence of its therapeutic potential in metastatic colorectal cancer care 显示文摘 | Martinelli E Morgillo F Troiani T | 2007 | Core Evid2007，2，2： | 1 |
| 16 | Sequence-dependent anti- proliferative effects of eytotoxic drugand epidermal growth factor receptor in- hibitors 显示文摘 | Morelli M P Cascone T Troiani T | 2005 | Annals of Oncology2005，16，4： | 1 |
| 17 | Anti-tumor activity of the combination of cetuximab, an anti-EGFR blocking monoclonal antibody and ZD6474, an inhibitor of VEGFR and EGFR tyrosine kinases显示文摘 | Morelli MP Cascone T Troiani T | 2006 | J Cell Physiol2006，208，2： | 1 |
| 18 | Erlotinib in cancer treatment 显示文摘 | Bareschino MA Schettino C Troiani T | 2007 | Ann Oncol2007，18，6： | 1 |
| 19 | Sequence and level of endogenous expression of calcium channel beta subunits in Schistosoma mansoni displaying different susceptibilities to praziquantel 显示文摘 | Valle C Troiani AR Festucci A | 2003 | Mol Biochem Parasitol2003，130，2： | 1 |
| 20 | Experimental detection of tet- ranitrogen显示文摘 | Cacace F Petris G de Troiani A | 2002 | Science2002，295，： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员